Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

  • STATUS
    Recruiting
  • End date
    Jun 4, 2024
  • participants needed
    250
  • sponsor
    Loxo Oncology, Inc.
Updated on 4 July 2021
chronic lymphocytic leukemia
rituximab
neutrophil count
idelalisib
bendamustine
btk inhibitor

Summary

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Description

This is a Phase 3 global, randomized, open-label study comparing LOXO-305 (Arm A) to investigator's choice of either idelalisib plus rituximab or bendamustine plus rituximab (Arm B) in CLL/SLL patients who have been treated with at least a covalent BTK inhibitor (BTKi). Patients may have discontinued the prior covalent BTKi due to disease progression (PD) or intolerance. Patients who have received venetoclax are eligible for the study. Eligible patients will be randomized in 1:1 to Arm A and Arm B.

Details
Condition Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma, b-cell small lymphocytic lymphoma
Treatment Rituximab, Bendamustine, Idelalisib, LOXO-305
Clinical Study IdentifierNCT04666038
SponsorLoxo Oncology, Inc.
Last Modified on4 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Confirmed diagnosis of CLL/SLL requiring therapy as defined by iwCLL 2018 criteria
Previously treated with a covalent BTK inhibitor
Eastern Cooperative Oncology Group (ECOG) 0-2
Absolute neutrophil count 0.75 109/L without granulocyte-colony stimulating factor support
Hemoglobin 8 g/dL not requiring transfusion support or growth factors within 14 days of Cycle 1 Day 1
Platelets 50 109/L not requiring transfusion support or growth factors within 14 days of C1D1. If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be (75 109/L)
AST and ALT 3.0 x upper limit of normal (ULN)
Total bilirubin 1.5 x ULN
Estimated creatinine clearance of 30 mL/min

Exclusion Criteria

Known or suspected Richter's transformation at any time preceding enrollment
Known or suspected history of central nervous system (CNS) involvement by CLL/SLL
Ongoing drug-induced liver injury
Active uncontrolled auto-immune cytopenia
Significant cardiovascular disease
History of allogeneic or stem cell transplantation (SCT) or chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days
Active hepatitis B or hepatitis C
Known active cytomegalovirus (CMV) infection
Active uncontrolled systemic bacterial, viral, fungal or parasitic infection
Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count
Clinically significant active malabsorption syndrome or inflammatory bowel disease
Prior exposure to non-covalent (reversible) BTK inhibitor
Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist
Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers and/or strong P-glycoprotein (P-gp) inhibitors
Vaccination with a live vaccine within 28 days prior to randomization
Patients with the following hypersensitivity
Known hypersensitivity, including anaphylaxis, to any component or excipient of LOXO-305, idelalisib, and bendamustine
Prior significant hypersensitivity to rituximab
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note